Product Description
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Insomnia|Stress Disorders, Post-Traumatic
Phase 1: Bipolar Disorder
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00907985 |
NCT00907985 | P1 |
Terminated |
Bipolar Disorder |
2010-06-10 |
2019-03-18 |
||
NCT00383786 |
06-M-0253 | P2 |
Completed |
Stress Disorders, Post-Traumatic |
2009-06-01 |
2019-03-21 |
Treatments |
|
NCT00606697 |
NKI110334 | P2 |
Completed |
Insomnia |
2008-05-07 |
2019-03-18 |
||
2007-004035-35 |
2007-004035-35 | P2 |
Completed |
Insomnia |
2008-05-07 |
2022-03-12 |
Treatments |